Efficiency and Safety of Magnesium Lactate Administration in the Reduction of Gestational Diabetes Incidence.

Status: Withdrawn
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Gestational diabetes, occurs during the second or third trimester of pregnancy, with no prior history of diabetes; this entity can be resolved at the end of pregnancy. Magnesium is the fourth most abundant mineral in the body, It plays an essential role in the regulation of insulin metabolism, in the functions of adenosine triphosphate. In Mexico, the prevalence of hypomagnesemia is 36.3% for women. Findings suggesting that magnesium supplementation may be a beneficial indication in metabolic glucose disorders. The hypothesis of this study is: that Magnesium lactate administration is safe and reduces the incidence of gestational diabetes.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 19
Maximum Age: 35
Healthy Volunteers: t
View:

• Pregnant women aged 19 to 35 years.

• 12th to 14th gestation weeks.

• Informed consent of the participant.

Locations
Other Locations
Mexico
Biomedical Research Unit. IMSS. Durango
Durango
Time Frame
Start Date: 2022-07-31
Completion Date: 2023-09
Treatments
Experimental: Magnesium
Magnesium lactate, 2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months plus baseline dietary magnesium requirement.
Placebo_comparator: Control
2 tablets orally every 12 hours of on inert placebo for three months plus baseline dietary magnesium requirement.
Sponsors
Leads: Coordinación de Investigación en Salud, Mexico

This content was sourced from clinicaltrials.gov

Similar Clinical Trials